Physician profile
Rupesh Manam
NPI 1184079519
$6,885.89
in general payments reported to CMS, 2019-2025
18 companies · $2,198 in 2025
The $2,198 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.71 · 2020: $252 · 2021: $715 · 2022: $812 · 2023: $2,082 · 2024: $751 · 2025: $2,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,003 · Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,003.48 |
| Food and Beverage | $2,027.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,748.31 | 2020-2025 | Triclip, Mitraclip |
| Boston Scientific Corporation | $1,015.13 | 2019-2025 | Watchman Access System |
| Heartflow, INC. | $502.56 | 2023-2025 | Ffrct |
| Biotronik INC. | $247.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.59 | 2022-2025 | Jardiance |
| Medtronic, INC. | $203.18 | 2021-2025 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $196.40 | 2022-2024 | Eliquis, Camzyos |
| Amgen INC. | $142.82 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $129.18 | 2023-2025 | |
| Novo Nordisk INC | $102.75 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic Vascular, INC. | $100.00 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.52 | 2022-2023 | Lifevest |
| Vital Connect, INC | $56.94 | 2024 | Vitalpatch Rtm |
| Astrazeneca Pharmaceuticals LP | $41.19 | 2022-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $31.59 | 2022-2023 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25.44 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.98 | 2022 | |
| Abiomed | $19.25 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupesh Manam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.